XTX Topco Ltd Acquires New Holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH)

XTX Topco Ltd bought a new position in Prestige Consumer Healthcare Inc. (NYSE:PBH) during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor bought 3,658 shares of the company’s stock, valued at approximately $264,000.

Other large investors have also recently bought and sold shares of the company. Quest Partners LLC raised its position in shares of Prestige Consumer Healthcare by 2,826.7% in the second quarter. Quest Partners LLC now owns 439 shares of the company’s stock worth $30,000 after buying an additional 424 shares in the last quarter. Northwestern Mutual Wealth Management Co. raised its holdings in shares of Prestige Consumer Healthcare by 562.3% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 510 shares of the company’s stock valued at $35,000 after acquiring an additional 433 shares in the last quarter. nVerses Capital LLC boosted its position in shares of Prestige Consumer Healthcare by 200.0% during the 3rd quarter. nVerses Capital LLC now owns 600 shares of the company’s stock valued at $43,000 after acquiring an additional 400 shares during the last quarter. Huntington National Bank grew its holdings in shares of Prestige Consumer Healthcare by 39.9% during the third quarter. Huntington National Bank now owns 635 shares of the company’s stock worth $46,000 after purchasing an additional 181 shares in the last quarter. Finally, Blue Trust Inc. increased its position in shares of Prestige Consumer Healthcare by 106.9% in the second quarter. Blue Trust Inc. now owns 867 shares of the company’s stock worth $63,000 after purchasing an additional 448 shares during the last quarter. 99.95% of the stock is owned by institutional investors.

Insider Transactions at Prestige Consumer Healthcare

In other news, EVP Adel Mekhail sold 9,063 shares of the company’s stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $82.00, for a total transaction of $743,166.00. Following the completion of the transaction, the executive vice president now directly owns 18,365 shares of the company’s stock, valued at approximately $1,505,930. This represents a 33.04 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider William P’pool sold 8,987 shares of the firm’s stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $81.85, for a total value of $735,585.95. Following the completion of the sale, the insider now directly owns 20,058 shares in the company, valued at $1,641,747.30. The trade was a 30.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 38,810 shares of company stock worth $3,187,300. Insiders own 1.60% of the company’s stock.

Prestige Consumer Healthcare Stock Performance

Prestige Consumer Healthcare stock opened at $78.79 on Thursday. The firm has a fifty day simple moving average of $78.86 and a two-hundred day simple moving average of $72.90. The company has a quick ratio of 2.10, a current ratio of 3.56 and a debt-to-equity ratio of 0.61. Prestige Consumer Healthcare Inc. has a twelve month low of $57.95 and a twelve month high of $86.36. The company has a market capitalization of $3.89 billion, a PE ratio of 19.17, a P/E/G ratio of 2.32 and a beta of 0.49.

Prestige Consumer Healthcare (NYSE:PBH) last issued its earnings results on Thursday, November 7th. The company reported $1.09 earnings per share for the quarter, meeting the consensus estimate of $1.09. The company had revenue of $283.79 million during the quarter, compared to analysts’ expectations of $282.09 million. Prestige Consumer Healthcare had a return on equity of 12.23% and a net margin of 18.54%. Prestige Consumer Healthcare’s quarterly revenue was down .9% compared to the same quarter last year. During the same period in the prior year, the business posted $1.07 EPS. Research analysts expect that Prestige Consumer Healthcare Inc. will post 4.44 EPS for the current year.

Analyst Ratings Changes

PBH has been the subject of several research analyst reports. DA Davidson reiterated a “buy” rating and set a $95.00 target price on shares of Prestige Consumer Healthcare in a research report on Monday, November 11th. Sidoti lowered shares of Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 target price for the company. in a research report on Monday, December 9th. Jefferies Financial Group restated a “hold” rating and set a $76.00 price target (up previously from $70.00) on shares of Prestige Consumer Healthcare in a research report on Tuesday, September 24th. Finally, StockNews.com upgraded Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a report on Wednesday. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $85.25.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.